Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
Explore this paper's citation graph
Summary
For effective DC vaccination the intrinsic tolerant state of the patient must be overcome and the development of efficient and safe adjuvants in antigen specific immunotherapeutic programs should be encouraged.
- Type
- review
- Published
- 2009-01-01
- Cited by
- 9
- References
- 184
- OpenAlex
- https://openalex.org/W25848639
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:19597043
Keywords
Immunotherapy, Antigen, Dendritic cell, Immunology, Vaccination
References
- HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading.
- Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII
- Phase I/II study of vaccination with dendritic‐like leukaemia cells for the immunotherapy of acute myeloid leukaemia
- Effect of costimulation and the microenvironment on antigen presentation by leukemic cells.
- CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells.
- The in-vitro generation of dendritic cells from blast cells in acute leukaemia.
- Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia.
- Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.
- Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor.
- Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents.
- Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.
- Leukemia-Derived Immature Dendritic Cells Differentiate into Functionally Competent Mature Dendritic Cells That Efficiently Stimulate T Cell Responses1
- Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells
- The allogeneic response and tumor immunity
- Vaccination with a Melan-A Peptide Selects an Oligoclonal T Cell Population with Increased Functional Avidity and Tumor Reactivity1
- WT1-specific serum antibodies in patients with leukemia.
- Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells.
- Toll-like receptors control activation of adaptive immune responses
- In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis.
- Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.
Cited by
- Dendritic cell immunotherapy
- Dendritic Cell-Based Immunotherapy for Myeloid Leukemias
- Dendritic cell vaccine therapy for acute myeloid leukemia: Questions and answers
- Dendritic cell vaccination in acute myeloid leukemia.
- Distinct expression of interferon‐induced protein with tetratricopeptide repeats (IFIT) 1/2/3 and other antiviral genes between subsets of dendritic cells induced by dengue virus 2 infection
- Identification and characterization of a Y chromosome-encoded gene overexpressed in acute myeloid leukaemia cells
- Cellular Immunotherapy for Hematologic Malignancies: Beyond Bone Marrow Transplantation.
- Paramunity-inducing Factors (PINDs) in dendritic cell (DC) cultures lead to impaired antileukemic functionality of DC-stimulated T-cells.
- Identification and Clinical Evaluation of the Receptor for Hyaluronic Acid-Mediated Motility ( RHAMM / CD 168 ) in AML Patients
Related papers
- Dendritic cell-based glioma immunotherapy (review).
- Dendritic cell vaccines.
- Use of interferon-α-induced dendritic cells in the therapy of patients with malignant brain gliomas
- [Dendritic cell therapy for malignant glioma].
- Dendritic-cell- and peptide-based vaccination strategies for glioma
- The relationship on dendritic cells and HIV-1 immunotherapy
- Tai Chi Chuan Increases Circulating Myeloid Dendritic Cells
- PU.1 is required for myeloid-derived but not lymphoid-derived dendritic cells.
- [Inflammatory dendritic cells].
- Activated and mature CD83-positive dendritic cells and interferon-gamma-positive cells in skin eruptions of secondary syphilis.